Printer Friendly

Ganoderol B: a potent a-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum.

[alpha]-Glucosidase inhibitor has considerable potential as a diabetes mellitus type 2 drug because it prevents the digestion of carbohydrates. The search for the constituents reducing [alpha]-glucosidase activity led to the finding of active compounds in the fruiting body of Ganoderma lucidum. The CHCl(3) extract of the fruiting body of G. lucidum was found to show inhibitory activity on [alpha]-glucosidase in vitro. The neutral fraction, with an IC(50) of 88.7 [mu]g/ml, had stronger inhibition than a positive control, acarbose, with an IC(50) of 336.7 [mu]g/ml (521.5 [mu]M). The neutral fraction was subjected to silica gel column chromatography and repeated p-HPLC to provide an active compound, (3[beta],24E)-lanosta-7,9(11),24-trien-3,26-diol (ganoderol B). It was found to have high [alpha]-glucosidase inhibition, with an IC(50) of 48.5 [mu]g/ml (119.8 [mu]M).

Phytomedicine. 2011 Sep 15;18(12):1053-5

COPYRIGHT 2013 LE Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Glucose and Cancer, Reishi, Tocopherol, and Hawthorn
Publication:Life Extension
Article Type:Brief article
Geographic Code:1USA
Date:Feb 1, 2013
Words:158
Previous Article:Ganoderma lucidum polysaccharide accelerates refractory wound healing by inhibition of mitochondrial oxidative stress in type 1 diabetes.
Next Article:Hypoglycemic effect and mechanism of a proteoglycan from Ganoderma lucidum on streptozotocin-induced type 2 diabetic rats.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters